News

Covance has closed its transaction with Merck to provide an array of genomics analysis services under a five-year $145m contract, and to acquire Merck’s Seattle-based Gene Expression Laboratory.

DURECT has signed a development and license agreement with Orient Pharma. Under the terms of the agreement, DURECT has granted development and commercialization rights to Orient Pharma, in

SyntheMed has received approval from the Ministry of Health of the Russian Federation for use of REPEL-CV in all patients who undergo open heart surgery. Reportedly, REPEL-CV is

4SC has reported the dosing of the first patient in its phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option

Geron has announced that its IND (Investigational New Drug application) for GRNOPC1 has been placed on clinical hold by FDA, pending the agency’s review of new nonclinical animal

Mylan has reported that Matrix Laboratories (Matrix) has received tentative approval from FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR). FDA approved its Abbreviated New Drug

Roche has announced that a phase III study of Avastin (bevacizumab), in combination with a range of chemotherapies, met its primary endpoint. The study met the objective of

Novavax has reported positive preclinical results with its 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. Under a collaborative agreement, the study has been conducted by the scientists

Omnia Biologics (Omnia) and Aparna Biosciences (AparnaBio) has signed a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical